2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1283

Risk Factors of Cancer-Associated Inflammatory Myopathies: A Multicenter Study
Abstract Number: 2872

Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database
Abstract Number: 2781

Risk of Cardiovascular Disease Associated with the Use of Glucocorticoids in Patients with Incident Systemic Lupus Erytematosus: A Population-based Study
Abstract Number: 805

Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Abstract Number: 2365

Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus
Abstract Number: 2368

Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study
Abstract Number: 732

Risk of Heart Valve Disease in Systemic Sclerosis
Abstract Number: 1395

Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab
Abstract Number: 1339

Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
Abstract Number: 2333

Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance
Abstract Number: 2434

Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database
Abstract Number: 2371

Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database
Abstract Number: 849

Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Abstract Number: 2053

Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis
Abstract Number: 2675

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].